Cargando…
Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial
BACKGROUND: Patient satisfaction with antipsychotic treatment is important. Limited evidence suggests that satisfaction is associated with symptom improvement and compliance. Predictors of patient satisfaction with antipsychotic medication were examined in a study of patients with a recent exacerbat...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1626455/ https://www.ncbi.nlm.nih.gov/pubmed/17054789 http://dx.doi.org/10.1186/1471-244X-6-45 |
_version_ | 1782130601562734592 |
---|---|
author | Gharabawi, Georges M Greenspan, Andrew Rupnow, Marcia FT Kosik-Gonzalez, Colette Bossie, Cynthia A Zhu, Young Kalali, Amir H Awad, A George |
author_facet | Gharabawi, Georges M Greenspan, Andrew Rupnow, Marcia FT Kosik-Gonzalez, Colette Bossie, Cynthia A Zhu, Young Kalali, Amir H Awad, A George |
author_sort | Gharabawi, Georges M |
collection | PubMed |
description | BACKGROUND: Patient satisfaction with antipsychotic treatment is important. Limited evidence suggests that satisfaction is associated with symptom improvement and compliance. Predictors of patient satisfaction with antipsychotic medication were examined in a study of patients with a recent exacerbation of schizophrenia. METHODS: Data are from a randomized, double-blind trial comparing risperidone (n = 152), quetiapine (n = 156), and placebo (n = 73). Medication Satisfaction Questionnaire (MSQ) was completed after 14 days of treatment and after 6 weeks at last study visit. RESULTS: Medication satisfaction at both time points was significantly associated in multiple regression analysis with improvement on 3 Positive and Negative Syndrome Scale (PANSS) factor scores (positive symptoms p < .01; uncontrolled hostility/excitement, p < .0005; anxiety/depression, p < .04) and treatment with risperidone (p < .03); at day 14, significant association was also found with older age (p = .01). At both time points, predictor variables explained over 30% of the variance in medication satisfaction. Change in Hamilton Depression Scale, prolactin levels, sex, and reported adverse events of extrapyramidal symptoms, sedation, and movement disorders were not significant predictors of satisfaction. Lower level of medication satisfaction at day 14 was associated with earlier discontinuation in the trial at week 6 end point. A focused principal components analysis of PANSS factors and MSQ suggested that medication satisfaction relates to 3 groups of factors in descending order of magnitude: lower levels of (a) uncontrolled hostility/excitement, (b) positive symptoms, and (c) negative symptoms, disorganized thoughts, and anxiety/depression. CONCLUSION: Results give further support that treatment satisfaction is positively associated with symptom improvement, particularly psychotic symptoms, and suggest that satisfaction may also be related to compliance, as those who were more satisfied remained in the trial for a longer period of time. TRIAL REGISTRATION NUMBER: Trial registration number NCT00061802 |
format | Text |
id | pubmed-1626455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-16264552006-10-28 Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial Gharabawi, Georges M Greenspan, Andrew Rupnow, Marcia FT Kosik-Gonzalez, Colette Bossie, Cynthia A Zhu, Young Kalali, Amir H Awad, A George BMC Psychiatry Research Article BACKGROUND: Patient satisfaction with antipsychotic treatment is important. Limited evidence suggests that satisfaction is associated with symptom improvement and compliance. Predictors of patient satisfaction with antipsychotic medication were examined in a study of patients with a recent exacerbation of schizophrenia. METHODS: Data are from a randomized, double-blind trial comparing risperidone (n = 152), quetiapine (n = 156), and placebo (n = 73). Medication Satisfaction Questionnaire (MSQ) was completed after 14 days of treatment and after 6 weeks at last study visit. RESULTS: Medication satisfaction at both time points was significantly associated in multiple regression analysis with improvement on 3 Positive and Negative Syndrome Scale (PANSS) factor scores (positive symptoms p < .01; uncontrolled hostility/excitement, p < .0005; anxiety/depression, p < .04) and treatment with risperidone (p < .03); at day 14, significant association was also found with older age (p = .01). At both time points, predictor variables explained over 30% of the variance in medication satisfaction. Change in Hamilton Depression Scale, prolactin levels, sex, and reported adverse events of extrapyramidal symptoms, sedation, and movement disorders were not significant predictors of satisfaction. Lower level of medication satisfaction at day 14 was associated with earlier discontinuation in the trial at week 6 end point. A focused principal components analysis of PANSS factors and MSQ suggested that medication satisfaction relates to 3 groups of factors in descending order of magnitude: lower levels of (a) uncontrolled hostility/excitement, (b) positive symptoms, and (c) negative symptoms, disorganized thoughts, and anxiety/depression. CONCLUSION: Results give further support that treatment satisfaction is positively associated with symptom improvement, particularly psychotic symptoms, and suggest that satisfaction may also be related to compliance, as those who were more satisfied remained in the trial for a longer period of time. TRIAL REGISTRATION NUMBER: Trial registration number NCT00061802 BioMed Central 2006-10-20 /pmc/articles/PMC1626455/ /pubmed/17054789 http://dx.doi.org/10.1186/1471-244X-6-45 Text en Copyright © 2006 Gharabawi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Gharabawi, Georges M Greenspan, Andrew Rupnow, Marcia FT Kosik-Gonzalez, Colette Bossie, Cynthia A Zhu, Young Kalali, Amir H Awad, A George Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial |
title | Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial |
title_full | Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial |
title_fullStr | Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial |
title_full_unstemmed | Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial |
title_short | Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial |
title_sort | reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1626455/ https://www.ncbi.nlm.nih.gov/pubmed/17054789 http://dx.doi.org/10.1186/1471-244X-6-45 |
work_keys_str_mv | AT gharabawigeorgesm reductioninpsychoticsymptomsasapredictorofpatientsatisfactionwithantipsychoticmedicationinschizophreniadatafromarandomizeddoubleblindtrial AT greenspanandrew reductioninpsychoticsymptomsasapredictorofpatientsatisfactionwithantipsychoticmedicationinschizophreniadatafromarandomizeddoubleblindtrial AT rupnowmarciaft reductioninpsychoticsymptomsasapredictorofpatientsatisfactionwithantipsychoticmedicationinschizophreniadatafromarandomizeddoubleblindtrial AT kosikgonzalezcolette reductioninpsychoticsymptomsasapredictorofpatientsatisfactionwithantipsychoticmedicationinschizophreniadatafromarandomizeddoubleblindtrial AT bossiecynthiaa reductioninpsychoticsymptomsasapredictorofpatientsatisfactionwithantipsychoticmedicationinschizophreniadatafromarandomizeddoubleblindtrial AT zhuyoung reductioninpsychoticsymptomsasapredictorofpatientsatisfactionwithantipsychoticmedicationinschizophreniadatafromarandomizeddoubleblindtrial AT kalaliamirh reductioninpsychoticsymptomsasapredictorofpatientsatisfactionwithantipsychoticmedicationinschizophreniadatafromarandomizeddoubleblindtrial AT awadageorge reductioninpsychoticsymptomsasapredictorofpatientsatisfactionwithantipsychoticmedicationinschizophreniadatafromarandomizeddoubleblindtrial |